These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28364032)

  • 1. Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.
    Ma Q; Steiger S; Anders HJ
    Physiol Rep; 2017 Apr; 5(7):. PubMed ID: 28364032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
    PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
    Zhang Y; Thai K; Kepecs DM; Gilbert RE
    PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.
    Oe Y; Kim YC; Sidorenko VS; Zhang H; Kanoo S; Lopez N; Goodluck HA; Crespo-Masip M; Vallon V
    Am J Physiol Renal Physiol; 2024 Feb; 326(2):F227-F240. PubMed ID: 38031729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling.
    Shentu Y; Li Y; Xie S; Jiang H; Sun S; Lin R; Chen C; Bai Y; Zhang Y; Zheng C; Zhou Y
    Int Immunopharmacol; 2021 Apr; 93():107374. PubMed ID: 33517222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease.
    van der Pluijm LAK; Koudijs A; Stam W; Roelofs JJTH; Danser AHJ; Rotmans JI; Gross KW; Pieper MP; van Zonneveld AJ; Bijkerk R
    Acta Physiol (Oxf); 2024 Mar; 240(3):e14108. PubMed ID: 38314444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
    Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
    Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
    Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
    Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
    Cassis P; Locatelli M; Cerullo D; Corna D; Buelli S; Zanchi C; Villa S; Morigi M; Remuzzi G; Benigni A; Zoja C
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
    Gilbert RE
    Kidney Int; 2014 Oct; 86(4):693-700. PubMed ID: 24257692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
    Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN
    Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.